Loading...
XNAS
QNRX
Market cap3mUSD
Apr 11, Last price  
5.37USD
1D
-2.19%
1Q
764.04%
Jan 2017
-99.29%
Name

Quoin Pharmaceuticals Ltd

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-90.02%
Rev. gr., 5y
%
Revenues
0k
0-280,0000-280,000000000
Net income
-8.96b
L+103,076.15%
-2,617,76415,317,00010,172,00015,317,000-1,560,401-1,764,052-8,518,668-9,277,453-8,686,573-8,962,472,000
CFO
-7.86b
L+99,809.47%
-1,984,168-3,767,008-4,978,620-6,573,927-1,298,858-1,338,633-5,720,090-8,480,732-7,864,429-7,857,309,000
Earnings
May 07, 2025

Profile

Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
URL
https://quoinpharma.com/
IPO date
Nov 01, 1989
Employees
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
9,528,465
9,370
9,361
Unusual Expense (Income)
NOPBT
(9,528,465)
(9,370)
(9,361)
NOPBT Margin
Operating Taxes
22
(104)
Tax Rate
NOPAT
(9,528,465)
(9,392)
(9,257)
Net income
(8,962,472)
103,076.15%
(8,687)
-6.37%
(9,277)
8.91%
Dividends
(65,266)
Dividend yield
11,380.02%
Proceeds from repurchase of equity
5,834
BB yield
-132.02%
Debt
Debt current
600
Long-term debt
Deferred revenue
Other long-term liabilities
2,323,733
2,924
3,520
Net debt
(3,623,343)
(10,695)
(12,853)
Cash flow
Cash from operating activities
(7,857,309)
(7,864)
(8,481)
CAPEX
(250)
Cash from investing activities
(1,888,282)
2,188
(10,149)
Cash from financing activities
10,967,736
5,217
14,008
FCF
(16,650,194)
(9,392)
1,741,357
Balance
Cash
3,623,343
10,695
12,854
Long term investments
Excess cash
3,623,343
10,695
12,854
Stockholders' equity
(55,165,792)
(46,203)
2,894,483
Invested Capital
66,694,198
54,791
(2,082)
ROIC
ROCE
EV
Common stock shares outstanding
4,689
901
404
Price
0.65
-86.73%
4.91
245.42%
1.42
-93.76%
Market cap
3,051
-30.96%
4,419
670.51%
574
-4.56%
EV
(3,620,292)
(6,276)
2,919,721
EBITDA
(9,428,465)
(9,266)
(9,257)
EV/EBITDA
0.38
0.68
Interest
714
Interest/NOPBT